期刊文献+

血清T3和人前梯度蛋白2及甲状腺抗体等在垂体瘤中的表达及意义 被引量:3

Expression and significance of serum T3,AGR2 and thyroid antibody in pituitary tumors
原文传递
导出
摘要 目的探讨血清甲状腺素T3、人前梯度蛋白2(AGR2)、甲状腺球蛋白抗体(TGAb)及促黄体生成素(LH)在垂体瘤中的表达及临床意义。方法选取2017年2月至2019年2月间空军军医大学第一附属医院收治的112例垂体瘤患者为研究组,另选取48名健康体检者为对照组。检测两组血清T3、AGR2、TGAb及LH在垂体瘤中的表达,并分析四者与临床病理及预后的关系。结果研究组血清甲状腺素T3、AGR2和TGAb均高于对照组,LH低于对照组,差异均有统计学意义(均P<0.05)。血清T3、AGR2、TGAb及LH表达水平与垂体瘤患者的年龄、临床分期、组织学分型和肿瘤直径等,差异无统计学意义(P>0.05)。而血清T3、AGR2、TGAb及LH表达水平与垂体瘤患者病理类型、是否复发和淋巴结转移密切相关,差异均有统计学意义(均P<0.05)。受试者工作曲线(ROC)分析显示,血清T3、AGR2、TGAb及LH水平诊断垂体瘤的曲线下面积(AUC)为0.867、0.930、0.949、0.917。甲状腺素T3敏感度、特异度为75.0%、91.7%,AGR2敏感度、特异度为90.2%、95.8%,TGAb敏感度、特异度为90.2%、91.7%,LH敏感度、特异度为90.2%、81.2%,均具有一定预测价值,差异均有统计学意义(均P<0.05)。Kaplan-Meier生存分析显示,甲状腺素T3、AGR2、TGAb及LH阴性组患者2年生存期均高于阳性组患者,差异均有统计学意义(均P<0.05)。结论血清T3、AGR2、TGAb及LH对垂体瘤的诊断价值较高,可作为垂体瘤临床诊断及预后评估的指标。 Objective To explore the expression and clinical significance of serum thyroid hormone triiodothyronine(T3),human anterior gradient protein 2(AGR2),thyroglobulin antibody(TGAb)and luteinizing hormone(LH)in pituitary tumors.Methods One hundred and twelve patients with pituitary tumors were selected and included in an experimental group at The First Affiliated Hospital of Air Force Medical University between February 2019 and February 2019.Another 48 healthy individuals who had physical examinations were selected as a control group.The expression of serum T3,AGR2,TGAb and LH in pituitary tumors was examined,and the relationship between these four markers and clinical pathology and prognosis were analyzed.Results The levels of T3,AGR2 and TGAb were significantly higher in the experimental group than in the control group(all P<0.05)and the levels of LH were lower than the control group(P<0.05).The serum T3,AGR2,TGAb and LH expression levels were not associated with age,clinical stages,tissue credit type,and tumor diameter(P>0.05).Instead,they were closely associated with the pathological type,recurrence,and lymph node metastasis in patients with pituitary tumors(all P<0.05).A receiver operator characteristic(ROC)curve analysis showed that the area under the ROC curve(AUC)of serum T3,AGR2,TGAb and LH for the diagnosis of pituitary tumors was 0.867,0.930,0.949 and 0.917,respectively.Sensitivity and specificity was 75.0%and 91.7%,respectively for thyroxine T3,90.2%and 95.8%,respectively for AGR2,90.2%and 91.7%,respectively for TGAb and 90.2%and81.2%,respectively for LH with certain predictive value(all P<0.05).Kaplan-Meier survival analysis showed that patients with negative thyroxine T3,AGR2,TGAb and LH had significantly higher 2-year survival than patients with thyroxine T3,AGR2,TGAb and LH(all P<0.05).Conclusion Serum T3,AGR2,TGAb and LH have a high value for the diagnosis of pituitary tumors,and can be used as an index for the clinical diagnosis and prognostic evaluation of pituitary tumors.
作者 陈晓燕 魏会刚 张平花 房玉杰 CHEN Xiao-yan;WEI Hui-gang;ZHANG Ping-hua;FANG Yu-jie(Department of Neurosurgery,The First Affiliated Hospital of Air Force Medical University,Xi'an 710032,China;Department of Endocrinology,The First Affiliated Hospital of Air Force Medical University,Xi'an 710032,China)
出处 《中国肿瘤临床与康复》 2021年第9期1032-1037,共6页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 垂体瘤 甲状腺素T3 人前梯度蛋白2 甲状腺抗体 促黄体生成素 Pituitary tumors Thyroxine T3 Human pregradient protein 2 Thyroid antibody Luteinizing hormone
  • 相关文献

参考文献14

二级参考文献66

  • 1马荣炜,杨国庆,陆菊明.原发性甲状腺功能减退症误诊为垂体瘤18例分析[J].临床荟萃,2005,20(18):1065-1066. 被引量:6
  • 2盛红晶,孙庆吉.原发性甲状腺功能减退症10例误诊分析[J].中国实用乡村医生杂志,2006,13(2):48-49. 被引量:1
  • 3张倩,杨振,张艳贞,王爱丽,安学丽,晏月明.蛋白质糖基化修饰的研究方法及其应用[J].生物技术通报,2006,22(1):46-49. 被引量:6
  • 4中华医学会内分泌学分会,中华医学会神经外科学分会,中国垂体腺瘤协助组.中国肢端肥大症诊治指南(2013年版)[J].中华医学杂志,2013,93(31):2106-2111.
  • 5AYUK J, SHEPPARD MC. Does acromegaly enhance mortality[J]. Rev Endocr Metab Disord, 2008, 9(1): 33-39.
  • 6NACHTIGALL L, DELGADO A, SWEARINGEN B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades[J]. Clin Endocrinol Metab, 2008, 93(6): 2035-2041.
  • 7OSAMURA RY, EGASHIRA N, KAJIYA H, et al. Pathology, pathogenesis and therapy of growth hormone (GH)-producing pi- tuitary adenomas: technical advances in histochemistry andtheir contribution[J]. Acta Histochemica et Cytochemica, 2009, 42(4):95-104.
  • 8MINEMATSU T, MIYAI S, KAJIYA H, et al. Recent progress in studies of pituitary tumor pathogenesis[J]. Endocrine, 2005, 28(1): 37-41.
  • 9LOPES MBS. Growth hormone-secreting adenomas: pathology and eell biology[J]. Neurosurgical focus, 2010, 29(4): 1-7.
  • 10MAZAL PR, CZECH T, SEDIVY R, et al. Prognostic relevance of intracytoplasmic eytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic pa- tients[J]. Clinical Neuropathology, 2010, 20(4): 163-171.

共引文献63

同被引文献38

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部